Assessment of platelet activation in several different anticoagulants by the Advia 120 Hematology System, fluorescence flow cytometry, and electron microscopy
In vivo platelet activation results are often confounded by activation induced in vitro during the preparative procedures. We measured ex vivo (basal) and in vitro (thrombin-induced) platelet activation in sodium citrate, ethylenediaminetetraacetic acid (EDTA), and Citrate Theophylline Dipyridamole...
Saved in:
| Published in: | Thrombosis and haemostasis Vol. 90; no. 5; p. 940 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Germany
01.11.2003
|
| Subjects: | |
| ISSN: | 0340-6245 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | In vivo platelet activation results are often confounded by activation induced in vitro during the preparative procedures. We measured ex vivo (basal) and in vitro (thrombin-induced) platelet activation in sodium citrate, ethylenediaminetetraacetic acid (EDTA), and Citrate Theophylline Dipyridamole Adenosine (CTAD) whole blood specimens. Determinations were made by measurements of platelet density (mean platelet component: MPC concentration) on the Advia 120 Hematology System. The MPC has been previously shown to correlate with a fluorescence flow cytometric method, also determined in this study, using the surface expression of CD62P. Moreover, platelet shape and structure changes in EDTA and CTAD anticoagulated whole blood specimens were characterized by transmission electron microscopy (TEM). Observations made using the Advia 120 Hematology System platelet density parameter, MPC, in the absence of thrombin were 25.7 +/- 0.9 g/dl, 27.9 +/- 0.9 g/dl and 24.8 +/- 1.2 g/dl in sodium citrate, EDTA and CTAD whole blood specimens, respectively. Addition of thrombin induced a significant change in platelet MPC for sodium citrate (21.9 +/- 1.9 g/dl; p<0.0001) and EDTA (23.2 +/- 0.9 g/dl; p<0.0001) whole blood specimens. In contrast, thrombin had no effect on MPC measured in whole blood taken into CTAD tubes. In vitro fluorescence flow cytometric platelet activation experiments measuring the percentage of platelets expressing anti-CD62P showed increase in sodium citrate specimens from 9.2 +/- 7.0 to 55.5 +/- 23.1 % (p<0.0001) and in EDTA specimens from 1.9 +/- 1.7 to 64.6 +/- 12.4 % (p<0.0001) after addition of thrombin. However, in blood taken into CTAD tubes, there was no significant change. Studies on platelets isolated from whole blood in CTAD showed activation by thrombin indicating that platelets in CTAD, while protected in its presence remained functional upon its removal. When observed by TEM over time, platelets in EDTA appear more activated and contain fewer granules than platelets in CTAD. We conclude that CTAD demonstrates in vitro platelet activation inhibition and may be useful in stabilizing ex vivo platelet activation. The novel platelet activation parameter, MPC, measured by an automated routine hematology system, using customized proprietary software, may be used in conjunction with CTAD, a stabilizing anticoagulant, to measure the ex vivo platelet activation state in whole blood specimens. TEM studies verify shape modifications and simultaneous retention of intracellular granules at early post-venipuncture time periods in CTAD specimens. |
|---|---|
| AbstractList | In vivo platelet activation results are often confounded by activation induced in vitro during the preparative procedures. We measured ex vivo (basal) and in vitro (thrombin-induced) platelet activation in sodium citrate, ethylenediaminetetraacetic acid (EDTA), and Citrate Theophylline Dipyridamole Adenosine (CTAD) whole blood specimens. Determinations were made by measurements of platelet density (mean platelet component: MPC concentration) on the Advia 120 Hematology System. The MPC has been previously shown to correlate with a fluorescence flow cytometric method, also determined in this study, using the surface expression of CD62P. Moreover, platelet shape and structure changes in EDTA and CTAD anticoagulated whole blood specimens were characterized by transmission electron microscopy (TEM). Observations made using the Advia 120 Hematology System platelet density parameter, MPC, in the absence of thrombin were 25.7 +/- 0.9 g/dl, 27.9 +/- 0.9 g/dl and 24.8 +/- 1.2 g/dl in sodium citrate, EDTA and CTAD whole blood specimens, respectively. Addition of thrombin induced a significant change in platelet MPC for sodium citrate (21.9 +/- 1.9 g/dl; p<0.0001) and EDTA (23.2 +/- 0.9 g/dl; p<0.0001) whole blood specimens. In contrast, thrombin had no effect on MPC measured in whole blood taken into CTAD tubes. In vitro fluorescence flow cytometric platelet activation experiments measuring the percentage of platelets expressing anti-CD62P showed increase in sodium citrate specimens from 9.2 +/- 7.0 to 55.5 +/- 23.1 % (p<0.0001) and in EDTA specimens from 1.9 +/- 1.7 to 64.6 +/- 12.4 % (p<0.0001) after addition of thrombin. However, in blood taken into CTAD tubes, there was no significant change. Studies on platelets isolated from whole blood in CTAD showed activation by thrombin indicating that platelets in CTAD, while protected in its presence remained functional upon its removal. When observed by TEM over time, platelets in EDTA appear more activated and contain fewer granules than platelets in CTAD. We conclude that CTAD demonstrates in vitro platelet activation inhibition and may be useful in stabilizing ex vivo platelet activation. The novel platelet activation parameter, MPC, measured by an automated routine hematology system, using customized proprietary software, may be used in conjunction with CTAD, a stabilizing anticoagulant, to measure the ex vivo platelet activation state in whole blood specimens. TEM studies verify shape modifications and simultaneous retention of intracellular granules at early post-venipuncture time periods in CTAD specimens. In vivo platelet activation results are often confounded by activation induced in vitro during the preparative procedures. We measured ex vivo (basal) and in vitro (thrombin-induced) platelet activation in sodium citrate, ethylenediaminetetraacetic acid (EDTA), and Citrate Theophylline Dipyridamole Adenosine (CTAD) whole blood specimens. Determinations were made by measurements of platelet density (mean platelet component: MPC concentration) on the Advia 120 Hematology System. The MPC has been previously shown to correlate with a fluorescence flow cytometric method, also determined in this study, using the surface expression of CD62P. Moreover, platelet shape and structure changes in EDTA and CTAD anticoagulated whole blood specimens were characterized by transmission electron microscopy (TEM). Observations made using the Advia 120 Hematology System platelet density parameter, MPC, in the absence of thrombin were 25.7 +/- 0.9 g/dl, 27.9 +/- 0.9 g/dl and 24.8 +/- 1.2 g/dl in sodium citrate, EDTA and CTAD whole blood specimens, respectively. Addition of thrombin induced a significant change in platelet MPC for sodium citrate (21.9 +/- 1.9 g/dl; p<0.0001) and EDTA (23.2 +/- 0.9 g/dl; p<0.0001) whole blood specimens. In contrast, thrombin had no effect on MPC measured in whole blood taken into CTAD tubes. In vitro fluorescence flow cytometric platelet activation experiments measuring the percentage of platelets expressing anti-CD62P showed increase in sodium citrate specimens from 9.2 +/- 7.0 to 55.5 +/- 23.1 % (p<0.0001) and in EDTA specimens from 1.9 +/- 1.7 to 64.6 +/- 12.4 % (p<0.0001) after addition of thrombin. However, in blood taken into CTAD tubes, there was no significant change. Studies on platelets isolated from whole blood in CTAD showed activation by thrombin indicating that platelets in CTAD, while protected in its presence remained functional upon its removal. When observed by TEM over time, platelets in EDTA appear more activated and contain fewer granules than platelets in CTAD. We conclude that CTAD demonstrates in vitro platelet activation inhibition and may be useful in stabilizing ex vivo platelet activation. The novel platelet activation parameter, MPC, measured by an automated routine hematology system, using customized proprietary software, may be used in conjunction with CTAD, a stabilizing anticoagulant, to measure the ex vivo platelet activation state in whole blood specimens. TEM studies verify shape modifications and simultaneous retention of intracellular granules at early post-venipuncture time periods in CTAD specimens.In vivo platelet activation results are often confounded by activation induced in vitro during the preparative procedures. We measured ex vivo (basal) and in vitro (thrombin-induced) platelet activation in sodium citrate, ethylenediaminetetraacetic acid (EDTA), and Citrate Theophylline Dipyridamole Adenosine (CTAD) whole blood specimens. Determinations were made by measurements of platelet density (mean platelet component: MPC concentration) on the Advia 120 Hematology System. The MPC has been previously shown to correlate with a fluorescence flow cytometric method, also determined in this study, using the surface expression of CD62P. Moreover, platelet shape and structure changes in EDTA and CTAD anticoagulated whole blood specimens were characterized by transmission electron microscopy (TEM). Observations made using the Advia 120 Hematology System platelet density parameter, MPC, in the absence of thrombin were 25.7 +/- 0.9 g/dl, 27.9 +/- 0.9 g/dl and 24.8 +/- 1.2 g/dl in sodium citrate, EDTA and CTAD whole blood specimens, respectively. Addition of thrombin induced a significant change in platelet MPC for sodium citrate (21.9 +/- 1.9 g/dl; p<0.0001) and EDTA (23.2 +/- 0.9 g/dl; p<0.0001) whole blood specimens. In contrast, thrombin had no effect on MPC measured in whole blood taken into CTAD tubes. In vitro fluorescence flow cytometric platelet activation experiments measuring the percentage of platelets expressing anti-CD62P showed increase in sodium citrate specimens from 9.2 +/- 7.0 to 55.5 +/- 23.1 % (p<0.0001) and in EDTA specimens from 1.9 +/- 1.7 to 64.6 +/- 12.4 % (p<0.0001) after addition of thrombin. However, in blood taken into CTAD tubes, there was no significant change. Studies on platelets isolated from whole blood in CTAD showed activation by thrombin indicating that platelets in CTAD, while protected in its presence remained functional upon its removal. When observed by TEM over time, platelets in EDTA appear more activated and contain fewer granules than platelets in CTAD. We conclude that CTAD demonstrates in vitro platelet activation inhibition and may be useful in stabilizing ex vivo platelet activation. The novel platelet activation parameter, MPC, measured by an automated routine hematology system, using customized proprietary software, may be used in conjunction with CTAD, a stabilizing anticoagulant, to measure the ex vivo platelet activation state in whole blood specimens. TEM studies verify shape modifications and simultaneous retention of intracellular granules at early post-venipuncture time periods in CTAD specimens. |
| Author | Okrongly, David Grant, Andrew M Lépine, Mariette Pujol-Moix, Nuria Boughrassa, Faiza Hernández, Angel Sabrinah Chapman, E Ahnadi, Charaf E |
| Author_xml | – sequence: 1 givenname: Charaf E surname: Ahnadi fullname: Ahnadi, Charaf E email: charaf.ahnadi@chus.qc.ca organization: Centre for Research and Evaluation in Diagnostics, Centre Hospitalier Universitaire de Sherbrooke, 3001, 12 Avenue Nord, Sherbrooke, Québec, Canada J1H 5N4. charaf.ahnadi@chus.qc.ca – sequence: 2 givenname: E surname: Sabrinah Chapman fullname: Sabrinah Chapman, E – sequence: 3 givenname: Mariette surname: Lépine fullname: Lépine, Mariette – sequence: 4 givenname: David surname: Okrongly fullname: Okrongly, David – sequence: 5 givenname: Nuria surname: Pujol-Moix fullname: Pujol-Moix, Nuria – sequence: 6 givenname: Angel surname: Hernández fullname: Hernández, Angel – sequence: 7 givenname: Faiza surname: Boughrassa fullname: Boughrassa, Faiza – sequence: 8 givenname: Andrew M surname: Grant fullname: Grant, Andrew M |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/14597991$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1kD9PwzAQxT0U0T-wMSNPTA3YiePUY1UBRarEAMyR7VxaIycutlOUL8NnxQiY7u7pp_fubo4mvesBoStKbinl5C4eSJGRPCNEVBM0IwUjGc9ZOUXzEN4JoZyJ8hxNKStFJQSdoa91CBBCB33ErsVHKyNYiFjqaE4yGtdj0-MAJ_DS4sa0LfgfVvbRaCf3g01dwGrE8QB43ZyMxDQneAudjM66_YhfxhChW-LWDs5D0NBrSIP7xHqMroPox2Xya3AK1tGnxM5o74J2x_ECnbXSBrj8qwv09nD_utlmu-fHp816l2lORMy0YnkhVMOV0KpSnDRtJZpcClJxWAlN26JinIDkVMEqyVJQ1iZFiFKwXOULdPPre_TuY4AQ686kTW26DtwQ6ooWjLGSJ_D6DxxUB0199KaTfqz_P5p_A8NWezY |
| CitedBy_id | crossref_primary_10_1097_MPA_0b013e31824bd89f crossref_primary_10_1111_j_1537_2995_2007_01167_x crossref_primary_10_1111_j_1537_2995_2005_04269_x crossref_primary_10_1161_CIRCRESAHA_121_319117 crossref_primary_10_1007_s00580_011_1345_x crossref_primary_10_1371_journal_pone_0038290 crossref_primary_10_1002_cyto_a_22892 crossref_primary_10_1002_cyto_a_23003 crossref_primary_10_3389_fimmu_2020_596841 crossref_primary_10_3109_09537104_2011_630112 crossref_primary_10_1080_07853890601040063 crossref_primary_10_1088_2057_1976_abbe72 crossref_primary_10_1016_j_thromres_2010_04_002 crossref_primary_10_1093_ajcp_aqw146 crossref_primary_10_1177_1040638720983791 crossref_primary_10_1111_j_1538_7836_2011_04283_x crossref_primary_10_1093_ajcp_aqw066 crossref_primary_10_1111_j_1751_553X_2009_01191_x crossref_primary_10_2460_ajvr_73_1_125 crossref_primary_10_5482_ha_1133 crossref_primary_10_1016_j_tox_2006_07_025 crossref_primary_10_5858_2007_131_293_EOAPTS crossref_primary_10_1097_MPH_0b013e318182e7a9 crossref_primary_10_1016_j_clinbiochem_2009_06_012 crossref_primary_10_1186_1742_2094_5_27 crossref_primary_10_1097_01_mbc_0000203862_85610_ac crossref_primary_10_1111_j_1939_1676_2007_tb03067_x crossref_primary_10_1186_1477_5956_7_15 crossref_primary_10_1186_s12864_024_10892_0 crossref_primary_10_1111_j_1939_165X_2007_tb00201_x crossref_primary_10_1002_cyto_a_20207 crossref_primary_10_1007_s11239_007_0034_8 crossref_primary_10_1016_j_jevs_2018_01_003 crossref_primary_10_1111_trf_12283 crossref_primary_10_1080_00365510500236283 crossref_primary_10_1016_j_transci_2007_02_006 crossref_primary_10_3390_ijms22179332 crossref_primary_10_1111_j_1939_165X_2010_00224_x crossref_primary_10_2302_kjm_53_210 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1160/th03-02-0097 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 14597991 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
| GroupedDBID | --- .55 .GJ 0R~ 0VX 123 1KJ 4.4 53G 5RE AAQQT ABJNI ABOCM ACGFO ACGFS AENEX AFFNX AHRSK ALMA_UNASSIGNED_HOLDINGS BR6 C45 CGR CS3 CUY CVF DU5 EBS ECM EIF EJD F5P H13 J5H NPM OVD P2P RTC RTE SJN TEORI X7M ZGI ZXP 7X8 ACNUY AGCGI |
| ID | FETCH-LOGICAL-c609t-cb4239bd6b9cb7b60df79d2a9076e89c1f37460ea61be8a90a914f460995942b2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 57 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000186504500027&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0340-6245 |
| IngestDate | Thu Jul 10 21:21:11 EDT 2025 Thu Jan 02 21:55:55 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c609t-cb4239bd6b9cb7b60df79d2a9076e89c1f37460ea61be8a90a914f460995942b2 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| PMID | 14597991 |
| PQID | 71344456 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_71344456 pubmed_primary_14597991 |
| PublicationCentury | 2000 |
| PublicationDate | 2003-11-01 |
| PublicationDateYYYYMMDD | 2003-11-01 |
| PublicationDate_xml | – month: 11 year: 2003 text: 2003-11-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Germany |
| PublicationPlace_xml | – name: Germany |
| PublicationTitle | Thrombosis and haemostasis |
| PublicationTitleAlternate | Thromb Haemost |
| PublicationYear | 2003 |
| SSID | ssj0016495 |
| Score | 1.9879538 |
| Snippet | In vivo platelet activation results are often confounded by activation induced in vitro during the preparative procedures. We measured ex vivo (basal) and in... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 940 |
| SubjectTerms | Anticoagulants - pharmacology Blood Platelets - cytology Blood Platelets - ultrastructure Blood Preservation Cell Size Citrates - pharmacology Edetic Acid - pharmacology Flow Cytometry - standards Hematologic Tests - instrumentation Hematologic Tests - standards Humans Microscopy, Electron - standards Platelet Activation Platelet Function Tests - instrumentation Platelet Function Tests - methods Thrombin - pharmacology |
| Title | Assessment of platelet activation in several different anticoagulants by the Advia 120 Hematology System, fluorescence flow cytometry, and electron microscopy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/14597991 https://www.proquest.com/docview/71344456 |
| Volume | 90 |
| WOSCitedRecordID | wos000186504500027&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8NAFB7qgnhx37d38NjQLNNJAoIUsfRi6aFCb2VWKGhS21Tpn_G3-l7S6Ek8eAlkhhnCzMvMW7-PsdsolLqtEuOZhKOBYo3zpFBtL5UJyrRMXGxVSTYR9_vJaJQOGuyuroWhtMr6TCwPapNr8pG3qOaR421_P33ziDOKYqsrAo01thGhIkMJXfHoJ4YgeMm54keU4B7ydp32LvzWsEdZRKHnl2BPv6mW5RXT3f3fx-2xnZVqCZ1KFvZZw2YHbOtpFTw_ZJ-dbxROyB1MX1DNxF0DKm2oHLMwyQBvSnJTQc2cgv0ZTphL4qzPijmoJaDSCB3zPpEQhD70CPa19M5DhX_eBPeyyGclUJS2-JJ_gF4W-astZssmzmegZt-BV0oIpNKY5RF77j4OH3reip7B08JPC08rAg9URqhUq1gJ37g4NaFEc1vYJNWBi2IufCtFoGyCzTINuMMWgjjjoQqP2XqWZ_aUQaQlR1UijnhouRJKpg6HGaW4MGgw2jN2U6_7GMWfYhoys_liPq5X_oydVFs3nlYoHWjTtClkGZz_OfaCbVcpeuRYuWQbDn98e8U29Xsxmc-uS6nCZ3_w9AUo_dt_ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Assessment+of+platelet+activation+in+several+different+anticoagulants+by+the+Advia+120+Hematology+System%2C+fluorescence+flow+cytometry%2C+and+electron+microscopy&rft.jtitle=Thrombosis+and+haemostasis&rft.au=Ahnadi%2C+Charaf+E&rft.au=Sabrinah+Chapman%2C+E&rft.au=L%C3%A9pine%2C+Mariette&rft.au=Okrongly%2C+David&rft.date=2003-11-01&rft.issn=0340-6245&rft.volume=90&rft.issue=5&rft.spage=940&rft_id=info:doi/10.1160%2Fth03-02-0097&rft_id=info%3Apmid%2F14597991&rft_id=info%3Apmid%2F14597991&rft.externalDocID=14597991 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0340-6245&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0340-6245&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0340-6245&client=summon |